Upgrades
• $Marqeta (MQ.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $15
• $Northwest Natural (NWN.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $53 (from $51)
• $Otis Worldwide (OTIS.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $82 (from $80)
• $Snowflake (SNOW.US)$ : Rosenblatt Upgrades to Buy from Neutral - PT $255 (from $325)
Downgrades
• $Eaton (ETN.US)$ : Barclays Downgrades to Underweight from Eq...

Upgrades
• $Aptiv PLC (APTV.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $112 (from $108)
• $ASM INTERNATIONAL NV SPON ADR EACH REP 1 ORD SHS (ASMIY.US)$ : Barclays Upgrades to Overweight from EqualWeight - PT $425 (from $300)
• $Brighthouse Financial (BHF.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $54 (from $53)
• $Cardinal Health (CAH.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $74 (from $54)
• $CrowdStrike (CRWD.US)$ : Goldman...

$Icon PLC (ICLR.US)$ nice

$Bristol-Myers Squibb (BMY.US)$ $Takeda Pharmaceutical (TAK.US)$ $PPD Inc (PPD.US)$ $Icon PLC (ICLR.US)$ Anyone have any input on some of these Biotech and Research stocks below. Some of them are trading at pretty high prices. Yet a few of them are priced low and was wondering if now would be a good time to get in and hold for a long time. Thank you for any input or discussion.
Bristol-Myers Squibb Company (BMY)
Takeda Pharmaceutical Company (TAK)
PPD Inc (PPD)
ICON Public Limited Company (ICLR)
Charles Rivers Laboratories International (CRL)
Laboratory Corporation of America (LH)
IDEXX Laboratories Inc (IDXX)
Bio-Rad Laboratories Inc (BIO)

$Icon PLC (ICLR.US)$
good Q2 report